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Summary
Human leukocytes were stimulated in vitro with peptides corresponding in sequence to the highly
variable helix of the a1 domain of various HLA-B and -C molecules. A CD4'CD8 - cytotoxic
T cell line, CTLAV, that is specific for the HLA-B7 peptide presented by HLA-DR11.1 was
obtained. The HLA-DR11.2 molecule, which only differs at three residues from HLA-DR11.1,
did not present the HLA-B7 peptide to CTLAV Peptides from the a1 domain helix of other
HLA-A and HLA-B molecules, but not HLA-C molecules, competed with the HLA-B7 peptide
for binding to HLA-DR11.1. A cell line (WT50) that coexpresses HLA-B7 and HLA-DR11.1
was killed by CTLAV in the absence ofany addedHLAB7 peptide. The processing and presentation
ofHLAB7 in these cells appears to be through the endogenous, and not the exogenous, pathway
of antigen presentation. Thus, Brefeldin A inhibits presentation and chloroquine does not.
Furthermore, introduction of purified HLA-B7 molecules into HLA-DR11.1', HLA-B7- cells
by cytoplasmic loading via osmotic lysis of pinosomes, but not by simple incubation, rendered
them susceptible to CTLAV killing. These results provide an example of class II major histo-
compatibility complex (MHC) presentation of a constitutively synthesized self protein that uses
the endogenous pathway ofantigen presentation. They also emphasize the capacity for presentation
of MHC peptides by MHC molecules.
T lymphocytes with a/0 antigen receptors interact with
ligands consisting of peptides bound to MHC glyco-
proteins (1-4). Study of T cell responses to a variety of for-
eign proteins has shown that peptides arising from endo-
genously synthesized proteins are frequently presented by class
I MHC molecules and that peptides derived from cellular
degradation of exogenously synthesized proteins are similarly
presentedby classII MHC molecules (5-11). There are, how-
ever, exceptions to these general rules for antigen presenta-
tion (12-15).
It is becoming increasingly clear that, in the absence of
foreign antigens, MHC molecules bind peptides derived from
self proteins and that these complexes play important roles
in thymic selection of the TCR repertoire, in the establish-
ment of tolerance and its subsequent maintenance (16-20).
Moreover, the interaction with peptide can, in the case of
class I, be critical for the correct assembly and cell surface
expression of the MHC molecule (21). It is therefore likely
that most, ifnot all, cell surface MHC molecules have a bound
peptide and that peptides contribute directly or conforma-
tionally to the structures contacted by all TCRs, including
those of alloreactive T cells.
Analysis of the xenogeneic response of murine T cells to
the human class I molecule, HLACw3, revealed that the an-
tigenic target was not native HLA-Cw3 but a peptide de-
rived from the processing of the HLA-Cw3 H chain and
presented by a murine class I MHC molecule (22). Examina-
tion of allogeneic responses has furnished additional examples
of the peptides derived from one MHC molecule being
presented to T cells by a second MHC molecule (23-25);
and raises the question as to the frequency ofsuch composite
MHC targets in the immune response to allogeneically trans-
planted tissues.
In this paper, we describe an in vitro immunization of
human peripheral blood leukocytes with synthetic peptides
derived from class I HLA H chains. This immunization led
to the stimulation of CTL specific for a composite MHC
target, consisting of a peptide derived from an allogeneic class
I molecule (HLA-B7) presented by a syngeneic class II MHC
molecule (HLA-DR11.1). In cells that express both HLA-B7
and HLA-DR11.1, the composite target can be formed "nat-
urally" and is detected by CTL. Processing of HLA-B7 and
its presentation by HLADR11.1 have properties that are char-
acteristicofthe endogenous pathway ofantigen presentation.
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the rules of antigen presentation, in which an endogenous
andconstitutively synthesized selfproteinis presentedby class
II MHC molecules.
Materials and Methods
Peptides.
￿
Synthetic peptides corresponding to residues 60-84
of HLA-A,B,C H chains (26) were synthesized by a solid phase
method using Fmoc chemistry (27). The peptides were desalted
by gelfiltration on a P-10 column in PBS (pH 7.3). Homogeneity
of the peptides was indicated by reverse-phase HPLC. The HLA-
B7.60-84 peptidewas sequencedby automaticEdmandegradation
using a gas phase sequencer and was shown to be >95% pure.
Establishment of Peptide B7.60-84-specific Cytotoxic T Cell Line
AV(CTLAV). Responder cells were peripheral bloodleukocytes
from three healthy donors: BC (HLAAll, 24; B27, 22; Cwl,w3;
DR8,12; DQ1,3), AV (HLAA2, 29; B27, w58; Cw2, w7; DR2,
11; DQl, 3), andJL (HLAA2, 31; B7,w57; Cw3; DRl, 3; DQl,
2). Peripheral blood leukocytes at 106 cells/ml were stimulated
with 10 hg/mlofamixture ofnine HLA:derivedpeptides in tripli-
cate macrowell (Costar, Cambridge, MA) cultures with sup-
plemented RPMI 1640. The immunizing peptides had sequences
corresponding to residues 60--84 of HLAB7, B13, B14, B27.1,
B27.2, B41, Cwt, Cw2.2, and Cw3. Medium was supplemented
with 10% FCS, 2MM L-glutamine,100Upenicillin, and100Ag/ml
streptomycin (Irvine Scientific, Santa Ana, CA). 3 d after initia-
tion of culture, rIIr2 was added at 10 U/ml. The cultures were
subsequently fed every 3 d with medium containing rIL2 at 50
U/ml and restimulated every 14 d with the mixture of peptides
using irradiated (4,000 rad), autologous peripheral blood leuko-
cytes (106 cells/ml) as APC. After four stimulations, irradiated
(10,000 rad) autologous EBVtransformed B cells (5
￿
x
￿
105
cells/ml) were used as APCinstead ofperipheral bloodleukocytes.
Cultures from donorAV gave substantial growth afterfive stimu-
lations. The expanded culture, designated CTLAV, was aliquoted
(10' cells per vial) and cryopreserved in medium containing
10% DMSO at -135°C. The CTIrAV line was shown to be
CD4*CDS- by indirect immunoassay using monoclonal anti-
CD4, -CD8, -HLA,and-DRantibodies andradioiodinated rabbit
anti-mouse Ig as the second-step reagent.
Cell Lines.
￿
EBVtransformed Bcell lines (EBVLCL) were used
both as antigen-presenting and target cells. Cell lines JBUSH,
SPOON, SWEI0007, BM21, BRIP, TUBO, J052839, JVM,
BM15, TISI, WT24, KT12,PF97387, BM16, BH, PITOUT, and
KAS011 were obtained from the 10th InternationalHistocompati-
bility Workshop. Cell lines AVOROS and LBA were established
by coculturing peripheral bloodleukocytes with supernatant con-
taining EBVvirusacid cyclosporin A(100 ng/ml). Cell lines ARB,
WT50, and GMR were obtained from Dr.J. Bodmer of the Im-
perial Cancer Research Fund, London. All cell lines were main-
tained by regular passage in supplemented medium.
Cell-mediated Cytotoxicity.
￿
CTIrAV was thawed and restimu-
latedwith themixtureofnine immunizing peptides (10hg/ml/pep-
tide) presentedby irradiated autologous EBVLCL in medium con-
taining rIL2 at 50 U/ml. In experiments after the identification
of B7.60-84 as thespecific antigen, CTIrAV were simulated solely
with the B7.60-84 peptideat 10 wg/ml. Cytotoxicity by CTIrAV
was measured 7 d after restimulation. Effector cells were diluted
in supplemented medium to yieldthe E/T ratios of20:1, 10:1,and
3:1. Target cells were labeled with 250 UCi of 5'Cr (Amersham
Corp., Arlington Heights, IL) in 0.3 ml of medium for 45 min.
The target cells were washed two times in medium, diluted to 5
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x 10' cells/ml, and 100 jA1 of cell suspension was added to
microwells containing medium or peptide (2 Kg/ml) for 30 min
before the addition of effector cells in 100 p,l. The cultures were
incubated for an additional 4 h in a 5% C02 incubator, and su-
pernatants were collected with harvesting frames (Skatron, Ster-
ling, VA) and counted for 5'Cr release. Percent cytotoxicity is
calculated using theformula: 100x (experimental release - spon-
taneousrelease)/(maximumrelease - spontaneous release). Spon-
taneous release and maximum release values were determined by
incubating target cells in medium or 0.1% Triton X-100 (Sigma
Chemical Co., St. Louis, MO), respectively. Results arepresented
as means t SD of triplicate determinations.
Treatment ofTarget Cells with Brefeldin A, Chloroquine, andHLA-
Al Peptide. The effect of treating target cells with Brefeldin A
andchloroquine on their susceptibility to CTIrAV killingwasex-
amined (28-30). Brefeldin A andchloroquine were added to "Cr-
labeled target cells (5 x 103 cells per microwell) at 15 wg/ml and
10 jiM, respectively. The inhibitors were preincubated with the
target cells for 30 min at 37°C in 5% C02 followed by an addi-
tional 30-min incubation with B7 peptide, B27peptide, or medium
before adding the effector cells. The inhibitors were present for
the duration of the 4-h "Cr release assay. The concentrations of
the inhibitors used in our experiments hadpreviously been shown
to inhibitthepresentation of either endogenous or exogenous an-
tigens (28-30), and did not show toxic effect when tested on
"Cr-labeled CTIrAV effector cells in a 4-h "Cr release assay. To
test the two inhibitors on WT50 target cells that constitutively
synthesize andpresentB7 antigens, thetarget cellswere preincubated
with a HLAAl peptide to replace B7 peptides in cell surface
B7/DR11.1 complexes before chromium labeling andintroduction
of the inhibitors. WT50 cells (2 x 106cells) were incubated with
peptide A1.60-84 (20 t~g/ml) for 24 h at 37°C in 5% C02. The
cellswere thenpelleted,washed with RPMI 1640, andlabeled with
250 iiCi of "Cr for 45 min. After being washed twice with
RPMI 1640, the target cells were resuspended in supplemented
medium in supplemented medium and added to microwells at 5
x 103 cells per well. Inhibitors and peptides were then added to
the target cells as described above.
Cytoplasmic Loading ofHLA Molecules.
￿
HLA molecules were
introduced into the cytoplasm of cells by osmotic lysis of pino-
somes containing exogenous HLA molecules using a modified
method of Moore et al. (31). Soluble HLA molecules were dis-
solved in hypertonic medium (0.5 mM sucrose, 10% [wt/volt poly-
ethylene glycol 1000, and 10 mM Hepes in RPMI, pH 7.2) at 0.3
mg/ml. "Cr-labeled target cells (2 x 106 cells) were washed twice
in PBS, resuspended in 0.5 ml of prewarmed hypertonic medium
containing solubleHLAA2or B7molecules, andincubatedat 37°C
for 10 min. Hypotonic medium (10 ml of 60% RPMI in water)
was then added to the cells for 3 min and washed twice in PBS.
The cell pellets were resuspended in supplemented medium at 5
x 10" cells/ml and used as target cells in a cytotoxicity assay.
mAbs.
￿
Hybridomas secreting theanti-DRmAb (L243), anti-
CD4 (OKT4), and anti-DR11 (SFR3.DR5) were obtained from
the American Type CultureCollection (Rockville, MD). Theanti-
CD8mAb (CamPath8c) wasa gift from Dr. H. Waldmann (Cam-
bridge University).The anti-DQ (anti-Leu-10) andanti-DP(B7/21)
mAbs were gifts from Dr. F. Brodsky.
Results
Cytotoxic T Cell Line CTLAVRecognizes a PeptideDerived
from the cr1 Helix ofHLA-B7 Molecules.
￿
Synthetic peptidescorresponding to residues 60-84 from the a1 helices of six
HLAB (B7, B13, B14, B27.1, B27.2, and B41) and three
HLA-C (Cwl, Cw2.2, and Cw3) molecules were cultured
in vitro with peripheral blood leukocytes from three healthy
donors. After repeated stimulation, the cells from one donor
(AV HLAA2, 29; B27, w58; Cw2, w7; DR2, 11; DQ1,
3) developed cytotoxicity that was specific for the autologous
B cell line when sensitized with the peptide mixture. Expan-
sion of these cells in rIL2 resulted in the CD4+, CD8 -
cytotoxic T cell line CTLAV
CTIrAV only lysed the AV B cell line in the presence of
peptides, showing that the CTL were specific for epitopes
provided by one or more of the peptides. Sensitization of AV
target cells with individual al peptides showed that significant
lysis was only seen in the presence of the HLAB7 peptide.
Moreover, the level of lysis obtained with this peptide was
equal or better than that obtained with the mixed peptides
(Fig. 1 A). This demonstrated that the HLAB7 peptide was
Cytotoxicity of AV Cells
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Figure 1.
￿
Presentation of an HLAB7 peptide by HLADR11-1
molecules. (A) Leukocytes repeatedly stimulated with a mixture of
-HLA-B,C peptides (at 10 Ag/ml/peptide) were tested for cytotoxicity
of autologous EBVLCL with or without the peptides present. Pep-
tides (2 Ag/ml) were incubated with target cells for 30 min before
the addition of effector cells, and were present throughout the cyto-
toxicity assay. (B) Cytotoxicity of autologous EBVLCL without pep-
tide (®), with B7.60-84 peptide (/), or with 827.60-84 peptide
(®) was measured in the presence of mAbs. Antibodies used were
monomorphic anti-class I HLA (W6/32), anti-DP (B7/21), anti-DQ
(anti-Leu-10), monomorphic anti-DR (L243), anti-DR11 (SFR3.DR5),
anti-CD8 (CamPath 8c), and anti-CD4 (OKT4). The target cells
were preincubated with mAbs (50 kg/ml) for 30 min before the ad-
dition of effector cells. Specific cytotoxicity was measured in a 4-h
51Cr release assay. Mean cytotoxicity of triplicate cultures with SD
was obtained at an E/T ratio of 10:1.
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the target antigen for CTLAV Peptide sensitization oftarget
cells with this peptide was dose dependent, saturation being
reached with 2 jAg/ml of peptide (data not shown).
HLA-B7.60-84 Peptide Is Presented to CTLAV by HLA-
DR11.1. The CD4 phenotype of the CTL suggested that
the antigen receptors of CTIrAV recognize the HLAB7 pep-
tide when presented by a class II HLA molecule. To address
this question directly, we assessed the cytotoxic activity of
CTLAV in the presence ofmAbs specific for HLA-DP, -DO,
and -DR, and HLA class I molecules (Fig. 1 B). Inhibi-
tion of cytotoxicity was observed with a monomorphic
anti-DR antibody (L243) and a specific anti-DR11 antibody
(SFR3.DR5), but not with anti-DP (87/21), anti-DQ (anti-
Leu-10), and anti-class I (W6/32) antibodies. In addition,
inhibition with anti-CD4 and not with anti-CD8 demon-
strated that the specific CTL were in fact CD4+ and CD8- .
These results show that the antigenic target of CTIrAV is
the HLAB7 peptide presented by the HLADR11 molecule
of donor AV The inhibition shown by anti-DR and anti-
CD4 mAbs shown in Fig. 1 B is -50%. Total inhibition
was observed with higher antibody concentrations, but such
concentrations resulted in some inhibition with nonspecific
antibodies.
A panel of 18 B cell lines of different HLA types was in-
cubatedwith the HLAB7.60-84 peptide and then screened
for lysisby CTLAV This analysis clearly confirmed that only
cells expressing HLADR11 were capable of presenting the
B7 peptide. However, not all cells typed as DR11 presented
the peptide (Fig. 2). Recently, HLADR11 has been split into
two subtypes, DR11.1 and DR11.2, that differ in the sequence
of their iP chains by three amino acids (32, 33). Presentation
of the B7 peptide correlated precisely with expression of the
DR11.1 subtype.
In VivoProcessing o,fHLA-B7 Results in Presentation by HLA-
DRILL CTLAV recognizes a synthetic peptide, with se-
quence derived from the HLAB7H chain, presented by HLA
DR11.1. This finding raised the possibility that cells from
individuals who express both B7 and DR11.1 would display
this, or a similar, complex upon their surfaces. Four cell lines
expressing both HLAB7 and HLADR11 were obtained.
However, they had not been previously assigned to one or
other subtype of HLADR11. On sensitization with peptide
HLAB7.60-84, two of the four cell lines (WT50 and ARB)
were lysed by CTIrAV and, on this basis, were typedas HLA
DR11.1; the other cell lines, LBA and GMR, were not lysed
by CTIYAV and were assigned as HLA-DR11.2 (Table 1).
In the absence ofpeptide sensitization, the WT50 cell line,
which is homozygous for HLA-B7 and HLADR11.1, was
lysed by CTLAV; and this killing was specifically blocked
by monoclonal anti-HLADR (Table 1). This result, com-
bined with the finding that cell fines expressing either B7,
DRILL, or neither ofthese molecules were refractory to lysis
by CT1rAV (Figs. 1 and 2), shows that functional complexes
ofB7 peptides bound by HLADR11.1 molecules are present
on the WT50 cell surface. Although specific lysis of WT50
cells was observed in all of 10 independent experiments, the
lysis was never as complete as when a saturating amount of
Cwt A
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814
827.1
841
st3
e7
827.2
Pool
A2.1
no peptide
No antibody
anti-lose l
anti-DP
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anti-CD4
~~I~ .
B
'nTable 1 .
￿
CTL-AV Can Lyse HLA-B7+, DR11.1 ` Target Cells in the Absence of B7.60-84 Peptide
" Cytotoxicity was measured in a 4-h s1Cr release assay .
t Peptides (2 jag/ml) and mAbs were added to target cells for 30 min before the addition of effector cells, and were present throughout the
assay .
S E/T ratios .
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Figure 2 .
￿
Restriction determinant for CTLAV .
Day 6 after being restimulated with B7.60-84 pep-
tide, CTLAV was assayed for cytotoxicity against
a panel of B cell lines sharing either class I or
class II allotypes with donor AV . Cytotoxicity was
measured in a 4-h 5ICr release assay against target
cells in the absence of peptide (®), preincubated
with B7.60-84 peptide (/), or a control peptide
B27.60-84 (®) . E/T ratios of 20:1, 10:1, and 3:1
were tested . Results presented are mean cytotox-
icity of triplicate cultures obtained at an E/T of
20 :1 .
Percent cytotoxicity'
HLA phenotype No peptide B7.60-84# B27.60-84
A. Target
cell A B Cw DR DP DQ 20S 10 3 20 10 3 20 10 3
SWEIG007 29 61 2 11.1 - 7 6±2 4±1 3±3 56±1 46±3 31±1 5±1 1±1 1±1
JVM 2 18 5 11.2 2 7 2±1 1±1 2±1 6±1 2±1 1±1 5±2 5±2 4±1
WT50 3 7 7 11 .1 - 7 21±2 14±1 10±1 40±1 35±1 27±1 20±115±211±1
ARB 26/327/512/7 11 .1/2 - - 7±1 7±2 6±2 51±4 41±2 34±1 4±4 5±3 4±2
LBA 68/30 7/57 7 11 .2/6 - 1/3 --1±2 -2±2 -4±2 1±2 -3±2 -2±2 5±5 0±2 3±2
GMR 3/68 7/8 3/4 11 .2/13 - 1/3 1±1 1±1 1±1 7±1 6±2 7±3 7±1 5±2 4±1
Percent cytotoxicity in the presence of rnAb (Ag/ml)
B. Target
cell Peptides mABt 0 6 12 25 50
WT50 None L243 33 ± 3# 29 ± 4 24 ± 3 16 ± 6 13 ± 4
W6/32 34±9 30±5 33±4 32±7
B7.60-84 L243 84 ± 5 81 ± 9 77 ± 6 69 ± 4 55 ± 5
W6/32 85±5 88±9 82±9 68±5
SWEI0007 None L243 5±4 5±6 7±4 7±4 2±3
W6/32 5±5 2±1 -4±5 4±2
B7 .60-84 L243 62±2 61±3 59±4 52±6 41±3
W6/32 58 ± 6 54 ± 4 55 ± 9 58 ± 6exogenous B7.60-84 peptide was added (Table 1) . Formation
of the appropriate complexes appeared to be limiting, such
that certain cells in the target population were killed and others
were not . Supporting this quantitative interpretation is the
finding that that the ARB cell line, which is heterozygous
for B7 and DR11.1, was not killed by CTIrAV unless exoge-
nous peptide was provided.
Presentation ofB7.60-841s Competedfor
￿
Homologous Pep-
tides from HLAA and B Molecules but not
by Homologous
HLAC.
￿
Of
nine homologous a1 peptides used for in vitro stimulation
ofT cells, only the HLA-B7 peptide was immunogenic . To
see if HLA-DR11 .1 specifically bound the B7 peptide, we
tested whether the homologous peptides from other HLA
A,$C molecules could compete with the B7 peptide for
binding to HLA-DR11 .1 . SWEIG007 cells, which express
HLA-DR11 .1 but not HLA-B7, were incubated with pep-
tides from the a1 helix of six HLA-A, seven HLA-B, and
threeHLAC molecules before sensitization with the B7 pep-
tide and testing for lysis by CTIAV A spectrum of inhibi-
tory capacity was observed for this panel of peptides (Fig .
3), with an apparent hierarchy among peptides derived from
HLA-A, -B, and -C products. Peptides from HLA-A mole-
cules were the strongest inhibitors, HLA-C peptides had no
significant effect, and intermediate levels of inhibition were
seen with HLA-B peptides (Fig. 3 A) . In no case was the
inhibition complete. The observed inhibition was unlikely
to result from direct rytotoxic effects upon the CTL, as a
4-h incubation of "Cr-labeled CT1rAV with each of the
peptides produced no peptide-specific lysis. Further evidence
for inhibition being due to competition at the level of an-
tigen presentation was the lack of inhibition observed when
effector T cells were preincubated with competing peptides,
washed, and then assayed for rytotoxic activity (data not
shown) .
We also examined whether preincubation of WT50 cells
with the panel of peptides had any effect upon the presenta-
tion of endogenous HLA-B7 peptides by the HLA-DR11.1
molecules of those cells. A similar hierarchy ofinhibition to
that seen with SWEI0007 cells was observed (Fig . 3, B and
C) . However, the degree of inhibition was greater than that
seen for SWEI0007 cells, and with peptides from HLAA1
and HLA-A2, the blocking ofcytolysis was almost complete .
These results show not only that many of thea1 helical pep-
tides can bind to HLA-DR11.1,but that they can effectively
displace the endogenously presented B7 peptide :
Presentation ofHLA-B7 Peptides by HLA-DR11 .1 in WT50
Cells Is Via the Endogenous Pathway . Processing ofHLA-B7
H chain by WT50 cells to give peptides that associate with
HLA-DR11 .1 molecules could occur by either an endoge-
nous or an exogenous pathway ofantigen presentation (34) .
The endogenous route could involve thebreakdown of newly
synthesized H chains that failed to associate with )32m, fold
correctly, or be routed to the plasma membrane; the exoge-
nous route could involve the internalization ofmature HLA-
B7 molecules from the cell surface or the endocytic uptake
of cellular debris, membrane fragments, or shed B7 mole-
cules from the culture medium .
To examine the latter possibility, we precultured target cells
in medium containing irradiated B7 expressing JY cells or
a lysate obtained by sonication ofthese cells . Such treatment
might be expected to feed B7 molecules into an exogenous
pathway ofprocessing. However, no effects ofthis treatment
were observed . Target cells expressing DR11.1, but not B7,
were not sensitized to lysis by preincubation with either a
JY cell extract or irradiated JY cells (Table 2), and neither
did culture with purified HLA-B7 molecules have any effect
(data not shown) . These results were not due to a resistance
to lysis induced by the preculture, asDR11.1 expressing targets
were still specifically sensitized by peptide B7.60-84 .
To determine whether HLA-B7 molecules could be pro-
cessed and presented through the endogenous pathway, soluble
B7 molecules were introduced into the cytoplasm ofDR11.1+
SWEI0007 target cells by osmotic rupture ofpinocytic vesicles
(31), and the cells were then tested for their susceptibility to
CTLAV killing. Cytotoxicity was observed against DR11.1+
target cells treated with B7 molecules, but not against
DR11.1 + target cells treated with A2 molecules nor against
the control DR11.2+ target cells treated with B7 (Table 2
B) . The consequence of treating these target cells with
Brefeldin A and chloroquine was also examined . Brefeldin
A has been shown to inhibit endogenous antigen presenta-
tion by blocking transport of newly synthesized MHC mol-
ecules from the endoplasmic reticulum to the Golgi complex
(29, 30), and chloroquine blocksMHC presentation of a va-
Figure 3.
￿
Competition of cytotoxicity by peptides of
various HLA allotypes. Target cells were SWEI0007 +
B7 peptide (A), WT50 (B), and WT50 + B7 peptide
(C) . Competing peptides at 100, 30, 10, or 3 ug/ml
were incubated with all three target cell populations fol-
lowed by incubation with B7.60-84 peptide (A and C)
or medium (B) for an additional 30 min before adding
effector cells . The peptides were present for the duration
of the 4-h s 1Cr release assay. Only results obtained at an
E/T ratio of 10:1 in the presence of threefold access of
competing peptides are shown.Table 2.
￿
Intracytoplasmic but not Endocytosed B7 Molecules Sensitize Target Cells to Killing by CTL-AV
A. Target cell
￿
Peptide
￿
Medium
￿
JY.Xt
￿
JY .Lyss
￿
WT24.Xt
￿
WT24.Lyss
SWEIG007
￿
None
￿
3 ± 1
￿
4 ± 1
￿
2 ± 2
￿
4 ± 1
￿
6 ± 1
B7.60-84
￿
42 ± 1
￿
49 ± 2
￿
47 ± 3
￿
47 ± 1
￿
44 ± 1
B27.60-84 3±1 7±1 8±1 3±1 7±1
JVM
￿
None
￿
7±1
￿
2±2
￿
5± 1
￿
2±2
￿
4± 1
B7.60-84
￿
8 ± 1
￿
4 ± 1
￿
6 ± 1
￿
7 ± 1
￿
3 ± 1
B27.60-84 8±1 7±1 8±1 6±1 3±6
riety of internalized antigens to T cells (10, 14, 28) . Partial
inhibition ofthekilling of SWEIG007 cells that had pinocy-
tosed B7 molecules and been osmotically shocked was ob-
served with Brefeldin A but not chloroquine, providing evi-
dencein favorofan endogenous pathway forB7 presentation
by HLA-DR11.1 (Table 2).
To test directly whetherprocessing andpresentation ofB7
by DR11.1 in WT50 cellsinvolves the endogenous or exoge-
nous pathways of antigen presentation, the effects of the in-
hibitors Brefeldin A and chloroquine upon presentation were
investigated. A unique aspect of this system, compared with
previous studiesof viral antigens (12-15), is that B7 is a con-
stitutively synthesized and presented self protein. To deplete
thelevels of theB7/DR11.1 complex, before administration
of the inhibitors, we preincubated WT50 cells with the tx1
helix peptide of HLA-A1. This peptideis effective at replacing
theendogenous B7 peptideboundto DR11.1 andis not rec-
ognized by CTIrAV (Fig. 3 B).
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Percent cytotoxicity of target cells treated with:'
* Cytotoxocity measured at E/T ratios of 20:1, 10:1, and 3:1 . Results presented are means ± SD of triplicate cultures measured at an E/T of
20:1.
t Target cells were incubated with irradiated (20,000 rad) JY .X (HLA-A2, 137) or WT24.X (HLA-A2, B27) cells for 24 h before the cytotox-
icity assay.
S Cell lysates were prepared by sonicating 7 x 106 JY or WT24 cells for 30 min, followed by centrigugation at 2,000 rpm for 15 min to re-
move chromatin and particulates. Lysate from either JY cells (JY.Lys) or WT24 cells (WT24.Lys) was added to target cells at a 1:25 dilution
for 48 h before assay.
II s'Cr-labeled target cells (2 x 106) were resuspended in 0.5 ml of hypertonic medium containing 0.3 mg/ml of HLA-B7 molecules (B7) or A2
molecules (A2) at 37°C for 10 min. Hypotonic medium was then added, and the cells were incubated at 37°C for 3 min and then pelleted.
The cells were resuspended in medium and tested in a 4-h cytotoxicity assay.
I E/T ratios.
Treatment of WT50 cells with chloroquine did not in-
hibit killing of WT50 by CTIYAV, providingfurther evidence
against theinvolvement of theexogenous pathwayof antigen
presentation. Positive evidence forthe involvement of the en-
dogenous pathway of antigen presentation was gained from
experiments with Brefeldin A. Preincubation of WT50 cells
with Brefeldin Aand theHLA-A1 peptide reproducibly gave
apartial inhibition (>50%) of lysis by CTIJAV. Pretreatment
with theHLA-A1 peptide alone hadno effect, showingthat,
in the absence of inhibitor, there was sufficient time after
the preincubation for new complexes of B7 and DR11.1 to
reach the surface. As expected, treatment with Brefeldin A
alone had no effect, due to the pre-existence of complexes
of B7 and DR11.1 at the cell surface. Further evidence for
the specificityof the effect ofBrefeldin A was that Brefeldin
A-treated WT50 cells still presented synthetic B7 peptide,
indicating that the inhibitor was not toxic for CTIrAV and
did not affect the DR11.1 molecules already present on the
Percent cytotoxicity of target cells treated with:"
B. Target cellll Peptide 201
Medium
10 3 20
Brefeldin
10 3 20
Chloroquine
10 3
SWEIG007(B7) None 13±5 10±1 5±2 5±1 4±2 3±2 10±4 9±1 5±1
B7.60-84 48±3 32**-3 19±2 42±3 30±1 17±3 47±3 36±2 21±2
B27.60-84 10±4 10±2 6± 1 5± 1 3±2 3±1 10±3 10±3 4±1
SWEI0007 (A2) None 1 ± 5 0 ± 1 2 ± 1 - 2 ± 1 2 ± 1 1 ± 2 - 2 ± 1 - 4 ± 1 -1 ± 1
B7.60-84 59±4 45±1 30±5 49±2 42±3 28±3 56±6 43±5 27±4
B27.60-84 -3±4 2±1 1±1 -1±1 1±1 2±1 1±1 1±1 2±1
JVM (117) 8 + 1 8 + 2 4 + 1
JVM(A2) 9+2 7+2 8+2' Target cells were incubated with 20 Ag/ml of HLA peptide A1 .60-84 for 24 h, washed, and labeled with S'Cr before testing in a cytotox-
ocity assay.
t Target cells were preincubated with Brefeldin A (15 Fig/ml) and chloroquine (10 AM) for 30 min before the addition of effector cells. The
inhibitors were present for the duration of the assay.
cell surface. In summary, the results are all consistent with
the endogenous pathway beingsolely responsible for the pre-
sentation of HLA-B7 peptides by HLA-DR11.1 on the sur-
face of WT50 cells.
Discussion
In general, it has been found that there is class discrimina-
tion in the processing and presentation ofantigens to T cells
(35). Thus, class I MHC molecules present peptides derived
from endogenous proteins synthesized within the APC,
whereas class II MHC molecules present peptides derived from
exogenous proteins synthesized elsewhere that enter the APC
by endocytosis. However, there are exceptions to these rules
(12-15); for example, Nuchtern et al. (15) recently analyzed
the recognition by CTL of an influenza peptide presented
by class II MHC molecules and showed that presentation was
via the endogenous pathway.
In the experiments reported here, we immunized human
PBL in vitro with peptides having sequences derived from
the highly variable cx1 domain helices of allogeneic and syn-
geneic HLAB,C molecules. As might have been expected from
this exogenous route of antigen delivery, CTL that recog-
nized a class I peptide presented by a class II MHC molecule
were obtained. Thus, target cells that express HLADR11.1
could be rendered susceptible to specific lysis by CTLAV by
preincubating them with the peptide from HLA-B7 but not
with the homologous peptides from 16 other HLAA,B,C
molecules. In these experiments, the antigen was provided
to the APC in an already processed form. However, the lysis
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by CTIrAV ofWT50, a cell line that expresses HLA-B7 and
HLA-DR11.1, showed that these cells could process HLA-
B7 and present it in the context of HLA-DR11.1. This pro-
cessing and presentation could be inhibited by Brefeldin A,
which blocks transport from the endoplasmic reticulum to
the Golgi (29, 30), and was unaffected by chloroquine, an
inhibitor of processing by the exogenous pathways (10, 14,
28). These results, indicating that HLAB7 presentation by
HLA-DR11.1 occurs via the endogenous pathway, are fur-
ther supported by experiments showing that HLA-DR11.1+,
HLA-B7- cells could process and present exogenously added
HLA-B if delivered to the cytoplasm, but not when deliv-
ered to endorytic vesicles.
This study thus provides a further exception to the rules
of antigen presentation, and another example of class II pre-
sentation by the endogenous pathways. A significant differ-
ence in the exception described here and those previously
reported (12-15) is that the antigen is a constitutively syn-
thesized selfprotein rather than viral proteins only made sub-
sequent to viralinfection. Thus, B7 is continuously presented
in WT50 cells. This property probably explains why Brefeldin
A treatment produced only a partial inhibition of presenta-
tion of HLA-B7 in WT50 cells.
The antigen receptors of CTLAV are highly specific for
the combination of HLA-DR11.1 and the peptide from the
HLAB7 cil helix; and they do not recognize HLA-DR11.2,
which only differs at three amino acids from HLA-DR11.1
(32, 33). However, peptide competition experiments show
that peptides from the a1 helix of various HLAA and -B
molecules, in addition to B7, also bind to the HLA-DR11.1
molecule.
Table 3. Elect of Brefeldin A
Target cell
and Chloroquine on
Peptide
Killing of HLA-B7+,
Percent
Medium
DR11.1 + Target Cells
cytotoxicity of target cells:'
Brefeldin At Chloroquinet
WT50 (A1) None 25 ± 2 9 ± 2 23 ± 3
B7.60-84 51 ±3 43±3 50±4
B27.60-84 21 ±1 11±3 22±2
WT50 None 19 ±1 20±3 18±2
B7.60-84 50 ± 1 50 ± 3 51 ± 2
B27.60-84 20 ±3 25±3 22±2
SWEIG007 (A1) None 4 ± 2 3 ± 3 3 ± 2
B7.60-84 70 ±1 60±2 71±3
B27.60-84 7 ± 2 7 t 1 6 ± 2
SWEI0007 None 8 ± 4 8 ± 2 6 ± 3
B7.60-84 75 ±2 70±3 74±2
B27.60-84 6 ± 4 6 ± 2 6 ± 4Endogenous presentation of B7 by DR11.1 was only ob-
served in one of two cell linesthat coexpress these molecules.
That it was the homozygous cell (WT50) that was lysed by
CTITAV and the heterozygous (ARB) cell line that was not,
suggests that the concentration of endogenously produced
B7 peptides is the limiting factor. This conclusion is consis-
tent with the observation that lysis ofWT50 was improved
by addition of exogenous B7 peptide. Another factor that
could contribute to the differencein B7 presentationby WT50
and ARB is the relative capacity of peptides derived from
the other MHC molecules expressed by the two cells to com-
pete with the B7 peptide for binding to HLADR11.1. Prece-
dent for such cellular differences in antigen presentation exist.
Bodmer et al. (36) have shown that two closely related HLA
molecules, HLA-A2.1 and HLA-Aw69, can both present a
synthetic influenza matrix peptide, M58-68, to A2.1-restricted
CTL. However, on infection with influenza virus only, HLA-
A2.1-expressing cells, and not HLA-Aw69-expressing cells,
were lysed by specific CTL, indicating that naturally processed
products of the influenza matrix protein failed to associate
with Aw69 molecules.
A critical issue is whether the class II MHC presentation
of endogenously processed self proteins described here, and
of viral proteins described by others (12, 13, 15), represent
curiosities or examples of a significant, if minor, pathway.
As far as we know, class I and class II MHC molecules are
both assembled in the same compartments of the endoplasmic
reticulum and pre-Golgi. At this stage ofbiosynthesis, class
I MHC molecules bind peptides, and a major question has
in fact been to explain why class II MHC molecules do not
generally bind and present peptides from this class I pool of
peptides to which they are exposed. One model proposed
is that invariant chain association blocks peptide access to
the binding site until the class II MHC molecule is targeted
to a cellular compartment containing peptides derived from
the exogenous pathway of antigen processing. A second model
is that endogenous processed peptides are picked up in the
endoplasmic reticulum by class II MHC molecules, but that
they are subsequently exchanged for exogenously processed
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